- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa | ||
| Mi | Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout | ||
| Mi | Eli Lilly outlays $7.3bn to acquire sleep drug biotech Centessa | ||
| Mi | Telomir seeks FDA approval for Telomir-1 to treat breast cancer | ||
| Mi | Symeres and Ambagon collaborate for colorectal cancer molecules | ||
| Di | Teva receives FDA approval for Prolia biosimilar | ||
| Di | Blackstone closes largest ever private funding investment round at $6.3bn | ||
| Di | uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies | ||
| Mo | Otsuka agrees to acquire Transcend Therapeutics for $1.22bn | ||
| Mo | Eli Lilly and Insilico Medicine forge $2.75bn AI-driven R&D pact | ||
| Mo | Novo Nordisk secures FDA approval for basal insulin Awiqli | ||
| Fr | Recordati sizes up €10.9bn CVC Capital acquisition offer | ||
| Fr | J&J's Darzalex nets first self-administered cancer injectable approval | ||
| Fr | Rocket's gene therapy Kresladi wins FDA approval in rare immune disease | ||
| Fr | Novartis to acquire Excellergy for $2bn upfront | ||
| Fr | Simulations Plus and three pharma companies collaborate on AI-driven drug development | ||
| 26.03. | Corcept's first-in-class ovarian cancer drug gains FDA approval | ||
| 26.03. | FDA opens door to feedback on 'unclear' national priority voucher pathway | ||
| 26.03. | Cognito Therapeutics and Ochsner partner for new brain health approaches | ||
| 26.03. | Daiichi Sankyo and Tempus AI collaborate on ADC clinical development | ||
| 25.03. | UCB banks on Georgia for $2bn biologics manufacturing facility | ||
| 25.03. | MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement | ||
| 25.03. | Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis | ||
| 25.03. | MSD and Quotient collaborate on IBD drug targets | ||
| 24.03. | Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.